{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:27:36Z","timestamp":1783006056531,"version":"3.54.5"},"reference-count":0,"publisher":"Knowledge E DMCC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJN"],"abstract":"<jats:p>Background: This retrospective cohort study was conducted to evaluate the efficacy and tolerance of rituximab (RTX) for the management of myasthenia gravis (MG).\r\nMethods: This retrospective cross-sectional study was conducted on 61 patients with refractory and non-refractory MG who received RTX. The Myasthenia Gravis Activities of Daily Living (MG-ADL) profile was used to assess MG symptoms and their effects on daily activities at the start of RTX and in the last follow-up. The Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS) scale has been used as an outcome measure after treatment with RTX in the 12th month and the last follow-up.\r\nResults: The mean age of the patients was 40.31 \u00b1 13.53 years (range: 15-78 years). Of 61 patients, eight (13.1%) were double seronegative, 29 (47.5%) had anti-acetylcholine receptor (AChR+) antibody, and 24 (39.3%) had anti-muscle-specific tyrosine kinase antibody (MuSK+). According to the mean rank table, the results of this study showed that the drug was more effective in improving the symptoms of MuSK+ patients compared to the other two groups (P = 0.006). The mean MG-ADL was 4.86 \u00b1 1.83 before treatment and 1.51 \u00b1 2.02 in the last follow-up visit. Paired t-test showed a significant association between MG-ADL before and after treatment in the last visit [t(55): 11.30, 95% confidence interval (CI): 2.79-3.99, P = 0.001)].\r\nConclusion: This retrospective study showed a considerable effect of RTX as induction therapy in patients with MG, especially those with MuSk+ MG.<\/jats:p>","DOI":"10.18502\/cjn.v21i2.10492","type":"journal-article","created":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T05:53:03Z","timestamp":1662270783000},"source":"Crossref","is-referenced-by-count":2,"title":["A retrospective study of the safety and efficacy of rituximab in Iranian patients with myasthenia gravis:  A single-center experience"],"prefix":"10.18502","author":[{"given":"Bentolhoda","family":"Ziaadini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Panahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Asghar","family":"Okhovat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Fatehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriar","family":"Nafissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7770","published-online":{"date-parts":[[2022,9,3]]},"container-title":["Current Journal of Neurology"],"original-title":[],"link":[{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/download\/10492\/9880","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/download\/10492\/9880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T17:08:06Z","timestamp":1734455286000},"score":1,"resource":{"primary":{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/view\/10492"},"secondary":[{"URL":"https:\/\/cjn.tums.ac.ir\/article_40008.html","label":"UNIVERSITY"},{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/view\/10492","label":"PUBLISHER"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":0,"URL":"https:\/\/doi.org\/10.18502\/cjn.v21i2.10492","relation":{},"ISSN":["2717-011X"],"issn-type":[{"value":"2717-011X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]}}}